InfuSystem (INFU) Stock Price, News & Analysis

Company Overview

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

Key Stats

• Today's Range: $8.04 to $8.24
• 50-Day Range: $7.54 to $9.25
• 52-Week Range: $5.74 to $9.97
• Volume: 102,689 shs
• Average Volume: 75,921 shs
• Market Capitalization: $171.99 million
• P/E Ratio: 138.50
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Strong Buy

INFU Stock Analysis - Frequently Asked Questions

How have INFU shares performed this year?

InfuSystem's stock was trading at $8.45 at the beginning of 2025. Since then, INFU shares have decreased by 4.3% and is now trading at $8.09.
View the best growth stocks for 2025 here.

How were InfuSystem's earnings last quarter?

InfuSystem Holdings, Inc. (NYSE:INFU) released its earnings results on Thursday, November, 7th. The company reported $0.08 earnings per share for the quarter, hitting analysts' consensus estimates of $0.08. The business had revenue of $35.32 million for the quarter, compared to the consensus estimate of $35.50 million. InfuSystem had a net margin of 1.12% and a trailing twelve-month return on equity of 2.78%.

Who are InfuSystem's major shareholders?

Top institutional investors of InfuSystem include Greenwood Capital Associates LLC (0.47%), ARS Investment Partners LLC (0.10%) and Legato Capital Management LLC (0.05%). Insiders that own company stock include Richard Dilorio, Christopher R Sansone, Carrie Lachance, Barry G Steele, Paul Andrew Gendron, R Rimmy Malhotra, Thomas Mark Ruiz, Addam Chupa, Ralph F Boyd Jr, Kevin Whitman, Kenneth D Eichenbaum and Gregg Owen Lehman.
View institutional ownership trends.

How do I buy shares of InfuSystem?

Shares of INFU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of InfuSystem own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InfuSystem investors own include Advanced Micro Devices (AMD), Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Home Depot (HD), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 2/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:INFU
• Previous Symbol: NYSE:INFU
• CUSIP: N/A
• CIK: 1337013
• Web: www.infusystem.com
• Phone: (248) 291-1210
• Fax: 800-455-4338
• Employees: 410
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $13.00
• High Stock Price Target: $13.00
• Low Stock Price Target: $13.00
• Potential Upside/Downside: +60.7%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 4.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.06
• Trailing P/E Ratio: 134.86
• Forward P/E Ratio: 53.93
• P/E Growth: N/A
• Net Income: $870,000.00
• Net Margins: 1.12%
• Pretax Margin: 2.65%
• Return on Equity: 2.78%
• Return on Assets: 1.41%

Debt

• Debt-to-Equity Ratio: 0.50
• Current Ratio: 1.98
• Quick Ratio: 1.59

Sales & Book Value

• Annual Sales: $125.79 million
• Price / Sales: 1.37
• Cash Flow: $0.62 per share
• Price / Cash Flow: 13.04
• Book Value: $2.47 per share
• Price / Book: 3.28

Miscellaneous

• Outstanding Shares: 21,260,000
• Free Float: 19,095,000
• Market Cap: $171.99 million
• Optionable: Optionable
• Beta: 1.53